For US Healthcare Professionals Important Safety Information Full Prescribing Information

Clinical Articles

"The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial"

Annals of Emergency Medicine

Clinical trial demonstrating how treatment with FabAV can reduce limb disability.

Read the Full Article

"Early Administration of Fab Antivenom Resulted in Faster Limb Recovery in Copperhead Snake Envenomation Patients"

Clinical Toxicology

Secondary analysis of a clinical trial demonstrating that patients treated with FabAV earlier had a significantly shorter time to full recovery than those treated late (median time: 17 versus 28 days, P=0.025).

Read the Abstract

"Antivenom Treatment Is Associated With Fewer Patients Using Opioids After Copperhead Envenomation"

Western Journal of Emergency Medicine

Secondary analysis of a clinical trial demonstrating that the proportion of patients using opioids for pain related to envenomation was smaller in the FabAV treatment group at all follow-up time points, and that the odds ratio of using opioids after hospital discharge among those who received placebo was 5.67 times that of those who received FabAV.

Read the Abstract

"Acute Adverse Events Associated With the Administration of Crotalidae Polyvalent Immune Fab Antivenom Within the North American Snake Bite Registry"

Clinical Toxicology

A retrospective study of 373 patients finds 2.7% incidence of adverse reactions overall, and a 1% incidence of severe adverse reactions.

Read the Abstract

"Incidence of Allergic Reactions to Crotalidae Polyvalent Immune Fab"

Clinical Toxicology

Retrospective study of 1340 CroFab patients finds low incidence (1.4%) of acute hypersensitivity reactions.

Read the Abstract

"Incidence of Immediate Hypersensitivity Reactions and Serum Sickness Following Administration of Crotalidae Polyvalent Immune Fab Antivenom: A Meta-analysis"

Academic Emergency Medicine

Systematic literature review and meta-analysis of immediate hypersensitivity reactions and serum sickness from FabAV.

Read the Abstract

"Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review"

Annals of Emergency Medicine

Study to estimate the proportion of patients with crotaline snake envenomation, treated with Crotalidae polyvalent immune Fab (ovine) antivenom, who develop medically significant late bleeding.

Read the Abstract

"Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning"

Annals of Emergency Medicine

First premarketing clinical study of CroFab, TAb001, to test the efficacy and safety of a new antivenom, affinity-purified, mixed monospecific crotalid antivenom ovine Fab in human subjects with minimal or moderate crotalid envenomation.

Read the Abstract

"A Randomized Multicenter Trial of Crotaline Polyvalent Immune Fab (Ovine) Antivenom for the Treatment of Crotaline Snakebite in the United States"

Archives of Internal Medicine

The second clinical trial of CroFab, TAb002, and the first randomized clinical trial of antivenom in the US showing efficacy and safety of CroFab in crotaline envenomation.

Read the Abstract
Choose CroFab icon

CroFab: Strength and speed when you need it most

Choose CroFab
CroFab efficacy checkmark icon

CroFab is clinically proven to achieve initial control of envenomation1

Examine the Data
CroFab dosing vial icon

Appropriate dosing achieves initial and sustained control of envenomation1

Learn How to Dose CroFab
REFERENCE

1. CroFab® [prescribing Information]. BTG International Inc. August 2018.